BRPI0517802A - efeito sinérgico de amlodipina e atorvastatina sobre a liberação de óxido nìtrico por células endoteliais aórticas - Google Patents

efeito sinérgico de amlodipina e atorvastatina sobre a liberação de óxido nìtrico por células endoteliais aórticas

Info

Publication number
BRPI0517802A
BRPI0517802A BRPI0517802-9A BRPI0517802A BRPI0517802A BR PI0517802 A BRPI0517802 A BR PI0517802A BR PI0517802 A BRPI0517802 A BR PI0517802A BR PI0517802 A BRPI0517802 A BR PI0517802A
Authority
BR
Brazil
Prior art keywords
atorvastatin
amlodipine
nitric oxide
endothelial cells
synergistic effect
Prior art date
Application number
BRPI0517802-9A
Other languages
English (en)
Inventor
R Preston Mason
Original Assignee
R Preston Mason
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Preston Mason filed Critical R Preston Mason
Publication of BRPI0517802A publication Critical patent/BRPI0517802A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EFEITO SINéRGICO DE AMLODIPINA E ATORVASTATINA SOBRE A LIBERAçãO DE óXIDO NìTRICO POR CéLULAS ENDOTELIAIS AóRTICAS. A combinação de amiodipina e atorvastatina age sintetizando sinergicamente a produção de NO. Além disso, a adição de um composto terciário complementa essa combinação de amiodipina e atorvastatina na produção de NO.
BRPI0517802-9A 2004-11-12 2005-10-28 efeito sinérgico de amlodipina e atorvastatina sobre a liberação de óxido nìtrico por células endoteliais aórticas BRPI0517802A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/987,271 US20050119270A1 (en) 2000-08-04 2004-11-12 Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release
PCT/US2005/039534 WO2006071351A2 (en) 2004-11-12 2005-10-28 Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release

Publications (1)

Publication Number Publication Date
BRPI0517802A true BRPI0517802A (pt) 2008-10-21

Family

ID=36615357

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517802-9A BRPI0517802A (pt) 2004-11-12 2005-10-28 efeito sinérgico de amlodipina e atorvastatina sobre a liberação de óxido nìtrico por células endoteliais aórticas

Country Status (6)

Country Link
US (1) US20050119270A1 (pt)
JP (1) JP2008519835A (pt)
BR (1) BRPI0517802A (pt)
CA (1) CA2587475A1 (pt)
MX (1) MX2007005784A (pt)
WO (1) WO2006071351A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2007019448A2 (en) * 2005-08-08 2007-02-15 Nitromed, Inc. Nitric oxide enhancing angiotensin ii antagonist compounds, compositions and methods of use
WO2007050585A2 (en) * 2005-10-24 2007-05-03 The Johns Hopkins University Use of a nitric oxide synthase modulator for the treatment of cardiac indications
AU2006321942A1 (en) * 2005-12-05 2007-06-14 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of disease
WO2008089148A1 (en) * 2007-01-12 2008-07-24 Biomarin Pharmaceutical Inc. Method of treating a metabolic or neuropsychiatry disorder with a bh4 derivative prodrug
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
WO2008131192A2 (en) * 2007-04-18 2008-10-30 The Trustees Of Columbia University In The City Of New York Crystalline cholestrol and prevention of atherosclerosis
RU2438188C1 (ru) * 2010-04-12 2011-12-27 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ коррекции эндотелиальной дисфункции комбинацией аторвастатина и резвератрола при l-name индуцированном дефиците оксида азота
WO2012079800A1 (en) * 2010-12-17 2012-06-21 Bruker Axs Gmbh Method and arrangement for characterizing fat bloom and quality of chocolate containing surfaces by x-ray diffraction
JP6176246B2 (ja) * 2012-06-25 2017-08-09 ニプロ株式会社 固形医薬錠剤およびその製造方法
WO2014007065A1 (ja) * 2012-07-06 2014-01-09 ニプロ株式会社 固形医薬錠剤およびその製造方法
US11653811B2 (en) * 2019-03-13 2023-05-23 Taikone Technologies Inc. Soap sponge
KR102730602B1 (ko) * 2021-06-24 2024-11-18 주식회사 종근당 칸데사르탄, 암로디핀 및 아토르바스타틴을 포함하는 약제학적 복합제제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861168A (en) * 1993-06-11 1999-01-19 The Board Of Trustees Of The Leland Stanford Junior University Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
US5645839A (en) * 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
HN2000000050A (es) * 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
WO2000076475A1 (en) * 1999-06-11 2000-12-21 Henceforth Hibernia, Inc. Prophylactic, therapeutic and industrial antioxidant compositions enhanced with stabilized atomic hydrogen/free electrons and methods to prepare and use such compositions
EP1212053A4 (en) * 1999-09-08 2004-08-11 Nitromed Inc METHODS FOR THE TREATMENT AND PROPHYLAXIS OF CONGESTIVE HEART FAILURE BY HYDRALAZIN COMPOUNDS AND ISOSORBIDE DINITRATE OR ISOSORBIDE MONONITRATE
AU7604400A (en) * 1999-09-21 2001-04-24 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
CA2388182A1 (en) * 1999-10-27 2001-05-03 Merck & Co., Inc. Lactonization process
AU780261B2 (en) * 1999-10-29 2005-03-10 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
HU227124B1 (en) * 2001-09-14 2010-07-28 Egis Gyogyszergyar Nyilvanosan Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin

Also Published As

Publication number Publication date
MX2007005784A (es) 2007-07-20
WO2006071351A2 (en) 2006-07-06
JP2008519835A (ja) 2008-06-12
CA2587475A1 (en) 2006-07-06
US20050119270A1 (en) 2005-06-02
WO2006071351A3 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
BRPI0517802A (pt) efeito sinérgico de amlodipina e atorvastatina sobre a liberação de óxido nìtrico por células endoteliais aórticas
CL2012000537A1 (es) Mezcla fungicida sinergica que comprende un compuesto derivado de 5-fluoro-2-{(4-metilbenzil)oxi}pirimidina-4-amino y otro fungicida; y composicion fungicida que la comprende.
PT2878307T (pt) Composição imunogénica.
EA201070015A1 (ru) Композиции, содержащие антитело
UY31563A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
UY31562A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
DE602006018563D1 (de) Durch seitlichen Druck lösbare Schnalle
CR20110581A (es) Preparación de solido
ITMI20051019A1 (it) Composizioni fungicide sinergiche
CR11656A (es) Composiciones fungicidas con 3'-bromo-2,3,4-6'-tetrametoxi-2'-6-dimetilbenzofenona
HN2006015130A (es) Asociacion entre la ferroquina y un derivado de artemisina para el tratamiento del paludismo
CR7962A (es) Clorhidrato de 1-(4-(2-piperidiniletoxi) Fenoxi)-2-(-4Metanosulfonifenil)-6-Hidroxinaftaleno Cristalino no solvatado
UY30009A1 (es) Compuestos benzoilpirazol y herbicidas que los contienen
CR7519S (es) Tarjeta con muesca
UA94914C2 (ru) Способ получения солей тиотропия
ATE533477T1 (de) Pharmazeutische zusammensetzungen enthaltend irbesartan
DE202005001617U1 (de) Kantenschutzband, insbesondere für Brandschutzglasscheiben
EA200702290A1 (ru) Мотилидные соединения
DE602006017660D1 (de) Maskenrohlinge
DE112006001054A5 (de) Türfeststeller
AR056549A1 (es) Panel que contiene bambu y fungicida
PA8627401A1 (es) Composiciones diuréticas de liberación prolongada
DE602006004679D1 (de) Kantenanleimgerät
BRPI0605917A2 (pt) intermediário cristalino de rosuvastatina
TR200800897U (tr) Granit, fayans ve seramik kesim makinesi.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/401 (2006.01), A61K 31/198 (2006.01), A61K